本帖最后由 老马 于 2013-3-13 13:43 编辑 F3 ]9 W1 l4 I1 n4 w0 g9 f' J
* S7 ^ ?0 ~5 \: Z9 W
健择（吉西他滨）+顺铂+阿瓦斯汀
, |+ y2 l% G# ?& g5 e Gemzar +Cisplatin + Avastin
+ ~& j) t0 x3 ]& D. u, zhttp://annonc.oxfordjournals.org/content/21/9/1804.full7 F) ]4 I, z3 r* e- [% t+ ]
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
- B: I2 f1 F' j2 T9 aPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point. ( B4 [: l" B9 _. \- r
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
( {7 o: @) j+ s
Cisplatin Gemzar Avastin.PDF
(329.84 KB, 下载次数: 847)
0 y% a) O% U9 @4 z7 ?华为网盘附件：
/ @# C% I( I2 B9 y【华为网盘】ava.JPG
! _3 x& u( }: u$ W& Y |
显身卡
